Granules India Completes Acquisition of Senn Chemicals
ECONOMY & POLICY

Granules India Completes Acquisition of Senn Chemicals

Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. 

The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. 

Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. 

Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. 

The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. 

Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). 

This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. 


(BSE)     

Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. (BSE)     

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code